Properties (76)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Fumapharm_AG
gptkb:Idec_Pharmaceuticals 2003 2006 2019 |
| gptkbp:CEO |
gptkb:Michel_Vounatsos
|
| gptkbp:clinicalTrials |
focus on personalized medicine
focus on digital health solutions focus on health disparities focus on data analytics focus on monoclonal antibodies focus on pain management focus on chronic disease management focus on diagnostics focus on Alzheimer's disease focus on amyotrophic lateral sclerosis focus on artificial intelligence in healthcare focus on biomarkers focus on clinical endpoints focus on clinical trial design focus on cognitive impairment focus on gene therapy focus on health economics focus on health technology assessment focus on integrated care models focus on multiple sclerosis focus on neurodegeneration focus on neuroinflammation focus on neuromuscular diseases focus on patient engagement focus on patient-reported outcomes focus on population health management focus on psychiatric disorders focus on quality of life measures focus on rare diseases focus on real-world evidence focus on regulatory science focus on small molecules focus on social determinants of health focus on spinal muscular atrophy focus on telemedicine focus on treatment adherence focus on treatment resistance focus on value-based care numerous ongoing trials |
| gptkbp:drugInterdiction |
biopharmaceuticals
|
| gptkbp:employees |
approximately 7,000
|
| gptkbp:founded |
1978
|
| gptkbp:founder |
gptkb:M._A._(Marty)_Houghton
|
| gptkbp:headCoach |
7,000
|
| gptkbp:headquarters |
gptkb:Cambridge,_MA
gptkb:Cambridge,_Massachusetts |
| https://www.w3.org/2000/01/rdf-schema#label |
Biogen Idec Inc.
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:market |
approximately $40 billion
|
| gptkbp:netIncome |
$3.5 billion (2020)
|
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Samsung_Bioepis gptkb:Ionis_Pharmaceuticals AbbVie |
| gptkbp:products |
gptkb:Tecfidera
gptkb:Spinraza gptkb:Avonex gptkb:Tysabri |
| gptkbp:researchAndDevelopment |
$2.5 billion (2020)
|
| gptkbp:researchFocus |
neurodegenerative diseases
multiple sclerosis neurological diseases spinal muscular atrophy |
| gptkbp:revenue |
$11.4 billion (2020)
|
| gptkbp:stockSymbol |
gptkb:BIIB
|
| gptkbp:subsidiary |
gptkb:Biogen_Idec_Ltd.
Biogen_International_GmbH |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.biogen.com
|